GTH Stock Overview
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment.
Genetron Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.26|
|52 Week High||US$16.94|
|52 Week Low||US$0.89|
|1 Month Change||-1.56%|
|3 Month Change||-8.70%|
|1 Year Change||-89.09%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-92.13%|
Recent News & Updates
|GTH||US Biotechs||US Market|
Return vs Industry: GTH underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: GTH underperformed the US Market which returned -9% over the past year.
|GTH Average Weekly Movement||11.6%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: GTH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: GTH's weekly volatility (12%) has been stable over the past year.
About the Company
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors.
Genetron Holdings Fundamentals Summary
|GTH fundamental statistics|
Is GTH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GTH income statement (TTM)|
|Cost of Revenue||CN¥205.32m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-6.16|
|Net Profit Margin||-101.39%|
How did GTH perform over the long term?See historical performance and comparison
Is GTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GTH?
Other financial metrics that can be useful for relative valuation.
|What is GTH's n/a Ratio?|
Price to Sales Ratio vs Peers
How does GTH's PS Ratio compare to its peers?
|GTH PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TCRX TScan Therapeutics
BOLT Bolt Biotherapeutics
HCWB HCW Biologics
GTH Genetron Holdings
Price-To-Sales vs Peers: GTH is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (13.1x).
Price to Earnings Ratio vs Industry
How does GTH's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: GTH is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Biotechs industry average (15.8x)
Price to Sales Ratio vs Fair Ratio
What is GTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.4x|
|Fair PS Ratio||5.3x|
Price-To-Sales vs Fair Ratio: GTH is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (5.3x).
Share Price vs Fair Value
What is the Fair Price of GTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GTH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GTH's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Genetron Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if GTH's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if GTH's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if GTH's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GTH's revenue (24.8% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: GTH's revenue (24.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GTH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Genetron Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GTH is currently unprofitable.
Growing Profit Margin: GTH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GTH is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare GTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: GTH has a negative Return on Equity (-54.08%), as it is currently unprofitable.
Discover strong past performing companies
How is Genetron Holdings's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GTH's short term assets (CN¥1.0B) exceed its short term liabilities (CN¥249.5M).
Long Term Liabilities: GTH's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥39.0M).
Debt to Equity History and Analysis
Debt Level: GTH has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GTH's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GTH has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 35.4% each year.
Discover healthy companies
What is Genetron Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GTH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GTH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GTH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GTH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sizhen Wang (45 yo)
Mr. Sizhen Wang has been Chairman at Genetron Holdings Limited since June 2021. He is the Co-Founder of Genetron Holdings Limited. He has been Director at Genetron Holdings Limited since April 2018 and has...
Experienced Management: GTH's management team is considered experienced (2.3 years average tenure).
Experienced Board: GTH's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genetron Holdings Limited's employee growth, exchange listings and data sources
- Name: Genetron Holdings Limited
- Ticker: GTH
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$114.159m
- Shares outstanding: 90.60m
- Website: https://www.genetronhealth.com
Number of Employees
- Genetron Holdings Limited
- Building 11
- 1-2 Floors
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/18 00:00|
|End of Day Share Price||2022/08/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.